Adaptive Biotechnologies Corporation (ADPT) Stock Analysis

58.0/100
Hold Not Halal Healthcare
Price $29.04
Market Cap $4.70B
52-Week Change +105.37%

Is ADPT a good investment?

Adaptive Biotechnologies Corporation (ADPT) has a Plutrex AI rating of 58.0/100 as of November 12, 2026, indicating a Hold consensus. The stock is not classified as halal-compliant. Key strength: MRD revenue grew 33% YoY to $66.2M on 43% volume growth and 7% ASP increase — the clonoSEQ commercial engine is demonstrably working, and NCCN Guideline inclusion (naming clonoSEQ explicitly for routine MRD assessment across the myeloma patient journey) creates a durable, protocol-embedded demand moat that is difficult to displace. This is structural demand entrenchment, not a one-time catalyst.. Main concern: Price has risen to $29.94, compressing implied upside to only 8.2% against the $32.40 analyst consensus — for a company with D/E of 2.27x (846% above industry), ROE of -37%, net margin of -23.7%, and revenue declining -10.7%, a minimum 12-18% discount to consensus is required ($32.40 × 0.87 = $28.19 upper bound of justified entry). Current price of $29.94 EXCEEDS this threshold, making new entry unattractive from a risk-adjusted perspective..

Investment Summary

ADPT at $29.94 is a pre-profitability diagnostics company with a genuinely compelling long-term thesis that is not yet reflected in current financials — and at current price, the risk/reward has compressed to an unattractive level for new capital. The core bull case rests on three pillars: (1) clonoSEQ's NCCN Guideline inclusion creating durable clinical demand for MRD testing in multiple myeloma, (2) MRD revenue growing 33% YoY to $66.2M on 43% volume growth validating the commercial engine, and (3) forward EPS growth of 82.3% next year and 41.6% 5-year CAGR — both approximately double the biotech industry average of 42.6% and 23.4% respectively. However, the financial reality is sobering: revenue growth of -10.7% (vs. industry +211.1%), net margin of -23.7% (vs. industry -0.86%), ROE of -37.0% (vs. industry -2.18%), and D/E of 2.27x (vs. industry 0.24x) confirm this is a deeply loss-making business with dangerous leverage. The stock has risen 5.5% from the prior $28.37 price to $29.94, analyst consensus has moved modestly from $31.58 to $32.40, and implied upside is now only 8.2% — below the 12-18% discount threshold required for ADPT's risk profile. HOLD for existing holders from prior entry zone; NO new capital at current price.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
25/100
Growth Potential
72/100
Valuation
38/100
Profitability
32/100
Debt Management
22/100
Analyst Sentiment
62/100
Technical Momentum
55/100
Insider Confidence
35/100
News Sentiment
90/100

Fundamental Analysis

ADPT's fundamentals remain bifurcated between an encouraging gross-level business model and catastrophic below-the-line performance. Gross margin of 71.6% (vs. industry 79.9%, a 10.4% discount) demonstrates pricing power and scalable unit economics — clonoSEQ generates strong per-test economics. Operating margin of -16.2% (vs. industry +5.4%, a 400% gap in absolute terms) reveals that SG&A and R&D spending obliterates all gross profit. Net margin of -23.7% (vs. industry -0.86%, a 2,644% gap) confirms substantial non-operating cost drag, likely interest expense on the convertible note structure underlying the 2.27x D/E ratio (vs. industry 0.24x, 846% excess leverage). ROE of -37.0% (vs. industry -2.18%, 1,599% worse) is the most alarming metric — book value is being destroyed at an extraordinary rate, making the 27.45x P/B ratio dangerous since the denominator is shrinking. FCF of -$8.8M is relatively contained, though the prior period showed -$24M, suggesting some improvement. Cash of $299M provides meaningful runway. The critical growth contradiction: revenue growth of -10.7% (vs. industry +211.1%) while analysts project 82.3% EPS growth next year — this requires implausible cost-cutting-driven margin expansion without revenue recovery, unless MRD's 33% revenue growth accelerates and becomes the dominant revenue line. No P/E or PEG calculable due to negative earnings; P/B of 27.45x on declining book value is speculative.

News Sentiment

Adaptive Biotechnologies is quietly building what could become a mandatory test for cancer patients — and doctors are starting to take notice. The company's clonoSEQ blood test, which detects the tiniest traces of cancer remaining after treatment (called Minimal Residual Disease, or MRD), just got a major credibility boost: the National Comprehensive Cancer Network updated its Multiple Myeloma Guidelines to explicitly name clonoSEQ as the standard for routine MRD assessment throughout a patient's entire treatment journey. That's the medical equivalent of getting your product written into the rulebook. The commercial results are starting to follow. As reported in Adaptive's Q3 2026 Earnings Call and Financial Results, MRD revenues jumped 33% year-over-year to $66.2 million, powered by a 43% surge in test volume and a 7% increase in average selling price — a rare combination that suggests both market penetration and pricing power simultaneously. The Q3 earnings release noted results topped analyst estimates on both earnings and revenues. Analyst commentary framed in 'Getting Paid Every Step Of The Way To A Myeloma Cure' captures the recurring revenue logic: every myeloma patient now potentially needs clonoSEQ testing at diagnosis, during treatment, after treatment, and in remission monitoring — creating a multi-touchpoint revenue stream per patient. The stock has climbed 5.5% over the past two weeks on this momentum, though some investors may want to wait for a pullback before jumping in.

Risk Assessment

PRIMARY RISK: Revenue growth reversal from +21.5% (prior period) to -10.7% (current) is the single most dangerous development — if the -10.7% trend persists, the 82.3% forward EPS growth projection becomes mathematically impossible without revenue recovery, and analyst consensus targets would face downward revision that would reprice the stock materially lower. SECONDARY RISK: D/E of 2.27x (now improved from prior 2.81x, but still 846% above industry 0.24x) with convertible note obligations creates refinancing risk in a rising rate environment — if cash burns faster than expected, the $299M buffer (down from $344M prior) shrinks the runway. MITIGATION: Stop loss at $21.75 (prior entry zone support) limits downside to 17.9% from the $26.50 midpoint entry, with 19.2% upside to the $32.40 consensus — a 1.89:1 ratio that is acceptable but not compelling. TAIL RISK: If MRD volume growth decelerates from 43%, the revenue trajectory worsens and the entire thesis collapses. UPSIDE RISK: FDA approval for new indications or additional NCCN guideline expansions could accelerate revenue recovery faster than modeled.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is ADPT a halal stock?

No, Adaptive Biotechnologies Corporation (ADPT) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for ADPT?

Adaptive Biotechnologies Corporation (ADPT) has a Plutrex AI rating of 58.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is ADPT a good investment?

According to Plutrex AI, ADPT has a Hold rating (58.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in ADPT?

US stocks like ADPT can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in ADPT?

Plutrex AI identifies the main risks for ADPT by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about ADPT

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open ADPT in ElBarake